Jubilant Pharmo

{
  "main_header": {
    "sid": 525933,
    "name": "Jubilant Pharmo",
    "stock_name": "Jubilant Pharmo",
    "full_name": "Jubilant Pharmova Ltd",
    "name_url": "stocks-analysis/jubilant-pharmo",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "933.40",
    "chg": -41.1,
    "chgp": "-4.22%",
    "dir": -1,
    "prev_price": "974.50",
    "mcapval": "15,234.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 530019,
    "symbol": "JUBLPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE700A01033",
    "curr_date": "Feb 06",
    "curr_time": "",
    "bse_nse_vol": "4.02 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 06, 2026",
    "traded_date_str": "2026 02 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/jubilant-pharmo-525933-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Are Jubilant Pharmova Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-jubilant-pharmova-ltd-latest-results-good-or-bad-3824784",
        "imagepath": "",
        "date": "2026-02-06 19:21:15",
        "description": "Jubilant Pharmova Ltd's latest financial results for Q3 FY26 reveal a complex situation characterized by significant revenue growth alongside a notable decline in profitability. The company reported consolidated net sales of ₹2,122.50 crores, reflecting a year-on-year growth of 16.51%, which marks a strong performance in terms of top-line revenue. However, this growth was overshadowed by a substantial drop in net profit, which fell to ₹55.90 crores, representing a decline of 44.60% compared to the same quarter last year.\n\nThe operating profit margin, excluding other income, contracted sharply to 13.68%, down from 17.44% in the previous quarter, indicating challenges in maintaining operational efficiency amid rising costs. This margin compression, coupled with a profit after tax (PAT) margin of only 2.64%, highlights the difficulties the company faces in translating revenue growth into sustainable profitabil..."
      },
      {
        "title": "Jubilant Pharmova Q3 FY26: Profit Plunges 53% as Margins Compress Despite Revenue Growth",
        "link": "https://www.marketsmojo.com/news/result-analysis/jubilant-pharmova-q3-fy26-profit-plunges-53-as-margins-compress-despite-revenue-growth-3824575",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/JubilantPharmov_quaterlyResult_3824575.png",
        "date": "2026-02-06 15:18:42",
        "description": "Jubilant Pharmova Ltd. reported a sharp 53.53% quarter-on-quarter decline in consolidated net profit for Q3 FY26, falling to ₹55.90 crores from ₹120.30 crores in the previous quarter, even as revenue reached an all-time high of ₹2,122.50 crores. The pharmaceutical manufacturer's shares tumbled 4.22% following the results announcement, closing at ₹933.40 on February 06, 2026, as investors reacted negatively to deteriorating profitability metrics and compressed margins across the board."
      },
      {
        "title": "Jubilant Pharmova Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jubilant-pharmova-ltd-is-rated-sell-3812570",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/JubilantPharmov_mojoScore_3812570.png",
        "date": "2026-01-31 10:10:20",
        "description": "Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Jubilant Pharmova Falls 8.79%: Technical Signals and Market Pressure Shape the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jubilant-pharmova-falls-879-technical-signals-and-market-pressure-shape-the-week-3803652",
        "imagepath": "",
        "date": "2026-01-24 17:04:20",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Jan 19:</strong> Stock plunges 5.07% amid broad market weakness</p>\n                    <p><strong>Jan 20:</strong> Death Cross formation signals potential bearish trend</p>\n                    <p><strong>Jan 21:</strong> Technical downgrade to Sell amid continued bearish momentum</p>\n                    <p><strong>Jan 22:</strong> Minor rebound with 2.11% gain</p>\n                    <p><strong>Jan 23:</strong> Week closes lower at ₹954.65, down 1.40% on the day</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,046.65</div></div>\n                    <di..."
      },
      {
        "title": "When is the next results date for Jubilant Pharmova Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-jubilant-pharmova-ltd-3802538",
        "imagepath": "",
        "date": "2026-01-23 23:16:00",
        "description": "The next results date for Jubilant Pharmova Ltd is scheduled for February 6, 2026...."
      },
      {
        "title": "Jubilant Pharmova Ltd Faces Bearish Momentum Amid Technical Downturn",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jubilant-pharmova-ltd-faces-bearish-momentum-amid-technical-downturn-3797623",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/JubilantPharmov_technicaldot_3797623.png",
        "date": "2026-01-21 08:01:58",
        "description": "Jubilant Pharmova Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. The company’s shares have declined sharply in recent weeks, underperforming the broader market and prompting a downgrade in its technical rating to a Sell, reflecting growing investor caution."
      },
      {
        "title": "Jubilant Pharmova Ltd Forms Death Cross, Signalling Potential Bearish Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jubilant-pharmova-ltd-forms-death-cross-signalling-potential-bearish-trend-3796935",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/JubilantPharmov_dealthcross_3796935.png",
        "date": "2026-01-20 18:00:27",
        "description": "Jubilant Pharmova Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s medium to long-term outlook."
      },
      {
        "title": "Jubilant Pharmova Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jubilant-pharmova-ltd-is-rated-sell-3795946",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/JubilantPharmov_mojoScore_3795946.png",
        "date": "2026-01-20 10:10:24",
        "description": "Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Jubilant Pharmova Ltd Faces Mildly Bearish Momentum Amid Technical Downgrade",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jubilant-pharmova-ltd-faces-mildly-bearish-momentum-amid-technical-downgrade-3791303",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/JubilantPharmov_technicaldot_3791303.png",
        "date": "2026-01-14 08:01:44",
        "description": "Jubilant Pharmova Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Recent technical indicators, including MACD, RSI, and moving averages, signal a cautious outlook for the pharmaceutical and biotechnology company as it navigates market pressures and investor sentiment."
      }
    ],
    "total": 375,
    "sid": "525933",
    "stock_news_url": "https://www.marketsmojo.com/news/jubilant-pharmova-525933"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "07-Feb-2026",
      "details": "Newspaper Publication",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Meeting Held On February 06 2026",
      "datetime": "06-Feb-2026",
      "details": "Outcome of Board Meeting held on February 06 2026",
      "source": "BSE"
    },
    {
      "caption": "Un-Audited Financial Results For Quarter And Nine Months Ended December 31 2025",
      "datetime": "06-Feb-2026",
      "details": "Un-audited Financial Results for quarter and nine months ended December 31 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Jubilant Pharmova Ltd has declared <strong>500%</strong> dividend, ex-date: 25 Jul 25",
          "dt": "2025-07-25",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Jubilant Pharmova Ltd has announced <strong>1:5</strong> stock split, ex-date: 17 Mar 06",
          "dt": "2006-03-17",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Are Jubilant Pharmova Ltd latest results good or bad?

2026-02-06 19:21:15

Jubilant Pharmova Ltd's latest financial results for Q3 FY26 reveal a complex situation characterized by significant revenue growth alongside a notable decline in profitability. The company reported consolidated net sales of ₹2,122.50 crores, reflecting a year-on-year growth of 16.51%, which marks a strong performance in terms of top-line revenue. However, this growth was overshadowed by a substantial drop in net profit, which fell to ₹55.90 crores, representing a decline of 44.60% compared to the same quarter last year. The operating profit margin, excluding other income, contracted sharply to 13.68%, down from 17.44% in the previous quarter, indicating challenges in maintaining operational efficiency amid rising costs. This margin compression, coupled with a profit after tax (PAT) margin of only 2.64%, highlights the difficulties the company faces in translating revenue growth into sustainable profitabil...

Read full news article

Jubilant Pharmova Q3 FY26: Profit Plunges 53% as Margins Compress Despite Revenue Growth

2026-02-06 15:18:42

Jubilant Pharmova Ltd. reported a sharp 53.53% quarter-on-quarter decline in consolidated net profit for Q3 FY26, falling to ₹55.90 crores from ₹120.30 crores in the previous quarter, even as revenue reached an all-time high of ₹2,122.50 crores. The pharmaceutical manufacturer's shares tumbled 4.22% following the results announcement, closing at ₹933.40 on February 06, 2026, as investors reacted negatively to deteriorating profitability metrics and compressed margins across the board.

Read full news article

Jubilant Pharmova Ltd is Rated Sell

2026-01-31 10:10:20

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Jubilant Pharmova Falls 8.79%: Technical Signals and Market Pressure Shape the Week

2026-01-24 17:04:20

Key Events This Week

Jan 19: Stock plunges 5.07% amid broad market weakness

Jan 20: Death Cross formation signals potential bearish trend

Jan 21: Technical downgrade to Sell amid continued bearish momentum

Jan 22: Minor rebound with 2.11% gain

Jan 23: Week closes lower at ₹954.65, down 1.40% on the day

Week Open

Rs.1,046.65

Read full news article

When is the next results date for Jubilant Pharmova Ltd?

2026-01-23 23:16:00

The next results date for Jubilant Pharmova Ltd is scheduled for February 6, 2026....

Read full news article

Jubilant Pharmova Ltd Faces Bearish Momentum Amid Technical Downturn

2026-01-21 08:01:58

Jubilant Pharmova Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. The company’s shares have declined sharply in recent weeks, underperforming the broader market and prompting a downgrade in its technical rating to a Sell, reflecting growing investor caution.

Read full news article

Jubilant Pharmova Ltd Forms Death Cross, Signalling Potential Bearish Trend

2026-01-20 18:00:27

Jubilant Pharmova Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s medium to long-term outlook.

Read full news article

Jubilant Pharmova Ltd is Rated Sell

2026-01-20 10:10:24

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Jubilant Pharmova Ltd Faces Mildly Bearish Momentum Amid Technical Downgrade

2026-01-14 08:01:44

Jubilant Pharmova Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Recent technical indicators, including MACD, RSI, and moving averages, signal a cautious outlook for the pharmaceutical and biotechnology company as it navigates market pressures and investor sentiment.

Read full news article

View All News